Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial-Reference-Cited by-同舟云学术

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial

Published:2017-05-15 Issue:8 Volume:52 Page:1194-1198
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Huhn S,Weinhold N,Nickel J,Pritsch M,Hielscher T,Hummel M,Bertsch U,Huegle-Doerr B,Vogel M,Angermund R,Hänel M,Salwender H J,Weisel K,Dürig J,Görner M,Kirchner H,Peter N,Graeven U,Lordick F,Hoffmann M,Reimer P,Blau I W,Jauch A,Dembowsky K,Möhler T,Wuchter P,Goldschmidt H

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201791.pdf

Reference15 articles.

1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128.

2. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328–e346.

3. Avet-Loiseau H, Corre J, Lauwers-Cances V, Chretien M-L, Robillard N, Leleu X et al. Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 Trial. Blood 2015; 126: 191.

4. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540–2547.

5. Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF . Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016; 51: 2–12.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma;Molecular Biology Reports;2024-09-09

2. Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant;HemaSphere;2024-04

3. Measurable residual disease in peripheral blood in myeloma: dream or reality;Current Opinion in Oncology;2023-08-13

4. Comparison of IGLV2‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma;The FEBS Journal;2023-06-08

5. Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM;Blood Advances;2023-01-27